Furthermore, Arezoo and colleagues found that OCT4 and NANOG co-expression in renal cancer is significantly associated with RCC subtypes and predicted poor prognosis of ccRCC patients; also, they evaluated CXCR4 as a novel renal CSC marker in renal cancer through immunohistochemistry (IHC)9,10. Here, POU5F1 is linked to renal carcinoma.